European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with ...
NEW YORK--(BUSINESS WIRE)--Jul 25, 2024-- Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX ® (fidanacogene elaparvovec), a gene therapy for the treatment of severe and …